BCRX vs. TSHA, NK, ADAP, VXRT, ATHA, MDGL, ALKS, FOLD, GERN, and NVAX
Should you be buying BioCryst Pharmaceuticals stock or one of its competitors? The main competitors of BioCryst Pharmaceuticals include Taysha Gene Therapies (TSHA), NantKwest (NK), Adaptimmune Therapeutics (ADAP), Vaxart (VXRT), Athira Pharma (ATHA), Madrigal Pharmaceuticals (MDGL), Alkermes (ALKS), Amicus Therapeutics (FOLD), Geron (GERN), and Novavax (NVAX). These companies are all part of the "medical" sector.
Taysha Gene Therapies (NASDAQ:TSHA) and BioCryst Pharmaceuticals (NASDAQ:BCRX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, media sentiment, valuation, earnings, institutional ownership, analyst recommendations, dividends and community ranking.
77.7% of Taysha Gene Therapies shares are held by institutional investors. Comparatively, 85.9% of BioCryst Pharmaceuticals shares are held by institutional investors. 2.7% of Taysha Gene Therapies shares are held by insiders. Comparatively, 4.8% of BioCryst Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Taysha Gene Therapies currently has a consensus price target of $7.00, indicating a potential upside of 78.57%. BioCryst Pharmaceuticals has a consensus price target of $14.00, indicating a potential upside of 114.72%. Given Taysha Gene Therapies' higher probable upside, analysts plainly believe BioCryst Pharmaceuticals is more favorable than Taysha Gene Therapies.
Taysha Gene Therapies has higher earnings, but lower revenue than BioCryst Pharmaceuticals. Taysha Gene Therapies is trading at a lower price-to-earnings ratio than BioCryst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
BioCryst Pharmaceuticals has a net margin of -58.69% compared to BioCryst Pharmaceuticals' net margin of -833.60%. Taysha Gene Therapies' return on equity of 0.00% beat BioCryst Pharmaceuticals' return on equity.
BioCryst Pharmaceuticals received 388 more outperform votes than Taysha Gene Therapies when rated by MarketBeat users. However, 74.17% of users gave Taysha Gene Therapies an outperform vote while only 66.43% of users gave BioCryst Pharmaceuticals an outperform vote.
Taysha Gene Therapies has a beta of 0.49, meaning that its share price is 51% less volatile than the S&P 500. Comparatively, BioCryst Pharmaceuticals has a beta of 1.87, meaning that its share price is 87% more volatile than the S&P 500.
In the previous week, BioCryst Pharmaceuticals had 2 more articles in the media than Taysha Gene Therapies. MarketBeat recorded 5 mentions for BioCryst Pharmaceuticals and 3 mentions for Taysha Gene Therapies. BioCryst Pharmaceuticals' average media sentiment score of 1.00 beat Taysha Gene Therapies' score of 0.92 indicating that Taysha Gene Therapies is being referred to more favorably in the media.
Summary
BioCryst Pharmaceuticals beats Taysha Gene Therapies on 11 of the 17 factors compared between the two stocks.
Get BioCryst Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for BCRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BCRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
BioCryst Pharmaceuticals Competitors List
Related Companies and Tools
